Guidelines-associated decrease in mortality with recombinant activated factor VII for refractory hemorrhage

Recombinant activated factor VII for acute intracerebral hemorrhage

Acute stroke is the third leading cause of death worldwide, exceeded only by coronary artery disease and cancer. There are two major subtypes of strokeischemic and hemorrhagic with 20-30% of all strokes being hemorrhagic in nature. The incidence of ischemic strokes has steadily declined by virtue of rigorous risk factor modification, but the same has not been possible for hemorrhagic strokes. M...

Rescue recombinant activated factor VII for neonatal subgaleal hemorrhage.

Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage

Intracerebral hemorrhage is the least treatable form of stroke and is associated with 30% to 50% mortality rate. Early hematoma growth occurs in 18% to 38% of patients scanned within 3 hours of intracerebral hemorrhage onset, and hematoma volume is an important predictor of poor outcome. Recombinant activated factor VII, a potent initiator of hemostasis, is currently approved for the treatment ...

Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage.

BACKGROUND Traumatic coagulopathy contributes to early death by exsanguination and late death in multiple organ failure. Recombinant Factor VIIa (rFVIIa, NovoSeven) is a procoagulant that might limit bleeding and improve trauma outcomes. METHODS We performed a phase 3 randomized clinical trial evaluating efficacy and safety of rFVIIa as an adjunct to direct hemostasis in major trauma. We stud...

Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII?

BACKGROUND AND PURPOSE In the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial, 80 microg/kg of recombinant activated factor VII (rFVIIa) significantly reduced intracerebral hemorrhage (ICH) expansion when given within 4 hours of onset. However, in contrast to an earlier Phase 2b study, rFVIIa did not improve survival or functional outcome. In this exploratory analysis, we hypothesized th...